Description

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer’s disease from healthy controls. Here we test whether immunosignatures correspond to

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer’s disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.

Reuse Permissions
  • Downloads
    PDF (2.3 MB)

    Details

    Title
    • Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer
    Contributors
    Date Created
    2012-07-16
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    Note
    • The article is published at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040201

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Hughes, A. K., Cichacz, Z., Scheck, A., Coons, S. W., Johnston, S. A., & Stafford, P. (2012). Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer. PLoS ONE, 7(7). doi:10.1371/journal.pone.0040201

    Machine-readable links